39
Participants
Start Date
February 17, 2020
Primary Completion Date
August 18, 2021
Study Completion Date
August 18, 2021
PfSPZ Challenge
Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
Palcebo
Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
M5717 30 mg
Participants received 30 mg single oral dose of M5717 capsule on Day 1.
M5717 60 mg
Participants received 60 mg single oral dose of M5717 capsule on Day 1.
M5717 80 mg
Participants received 80 mg single oral dose of M5717 capsule on Day 1.
M5717 100 mg
Participants received 100 mg single oral dose of M5717 capsule on Day 1.
M5717 200 mg
Participants received 200 mg single oral dose of M5717 capsule on Day 1.
Placebo
Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
M5717 60 mg
Participants received 60 mg single oral dose of M5717 capsule on Day 5.
M5717 100 mg
Participants received 100 mg single oral dose of M5717 capsule on Day 5.
M5717 200 mg
Participants received 200 mg single oral dose of M5717 capsule on Day 5.
Leiden University Medical Center, Leiden
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY